Sign in
Taking people in FinlandPhase 2

Tests estradiol patches and exercise for side effects of prostate cancer hormone therapy

Tests estradiol patches to ease sexual side effects in men with prostate cancer.

Key facts

Who runs it
Varsinais-Suomen hyvinvointialue
Where
Jyvaskyla, Tampere, and Turku, FinlandSee the 4 sites
Registry title
Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTRACISE)
Status
Recruiting
Phase
Phase 2
People taking part
310 people, planned
Started
1 Sept 2024
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
7 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has not spread, who are starting radiotherapy together with hormone treatment (ADT) for at least one year.

Age
Over 18 years.
Sex
Men only.
Disease stage
Localized prostate cancer, not low-risk, with no distant metastasis in bone, lymph nodes or soft tissue.
Earlier treatment
Starting radiotherapy with adjuvant ADT for at least one year. No ongoing glucocorticoid treatment.

Main reasons for not taking part

  • Low-risk prostate cancer
  • Diabetes mellitus
  • Past or current venous thromboembolism, or a heart event or stroke in the last 12 months
  • Cardiac pacemaker
  • Allergy to estradiol or leuprorelin, or a condition or medicine that rules out estradiol or leuprorelin

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Men with localized PCa starting radiotherapy with adjuvant ADT at least for one year
  • Adults (age over 18 years)
  • Sufficient performance status ECOG 0-1
  • Willingness to participate and signed consent
  • Body mass index between 18.5 – 30.0

Who cannot take part

  • Prior cardiovascular event or stroke (<12 months)
  • Concurrent glucocorticoid treatment
  • Known allergy to estradiol or leuprorelin
  • Cardiac pacemaker
  • Diabetes Mellitus
  • Past or current venous thromboembolism
  • Other untreated or unstable malignancy in risk of recurrence/progression (as judged by the treating physician)
  • Any medication or condition considered as a contraindication to estradiol (allergy to adjuvant compounds (carbomer, trolamine), history with thromboembolic disorders (protein C, protein S, or antithrombin deficiency), porphyria, acute or previous liver disease, drugs with cytochrome P450 enzyme metabolism (anticonvulsants: phenobarbital, phenytoin, carbamazepine; anti-infectives: rifampicin, rifapentine, nevirapine, efavirenz; and St. John's wort)) or leuprorelin (allergy to adjuvant compounds (polylactic acid), Qt-time prolonging drugs (quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide, methadone, moxifloxacin, antipsychotics)
  • Patients with low-risk PCa
  • Physical disabilities for regular exercise
  • Expected poor compliance or expected survival time of less than one year
  • Patients with expected adjuvant ADT for less than one year
  • Distant bone, lymph node, or soft tissue metastasis

Where in Finland

  • Central Finland Hospital District Central Finland Hospital NovaJyvaskyla, FinlandTaking people
  • University Of JyvaskylaJyvaskyla, FinlandTaking people
  • Tampere University HospitalTampere, FinlandTaking people
  • Varsinais-Suomen hyvinvointialueTurku, FinlandTaking people

About the trial

What the trial wants to find out

To estimate the efficacy of E2 in improving sexual dysfunction during ADT.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTRACISE)
Plain-language title
Tests estradiol patches and exercise for side effects of prostate cancer hormone therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
7 October 2026